PharmaCrunch

Top 10 Pharmaceutical Companies 2015 – Globally

Top 10 Pharmaceutical Companies 2016

  1. Johnson & Johnson (U.S.)
  2. Hoffmann-La Roche AG (Switzerland)
  3. Pfizer Inc. (U.S.)
  4. Novartis AG (Switzerland)
  5. Bayer AG (Germany)
  6. Merck & Co., Inc. (U.S.) 
  7. GlaxoSmithKline plc (U.K.) 
  8. Sanofi (France) 
  9. Gilead Sciences, Inc. (U.S.)
  10. AstraZeneca plc (U.K.)

 

  • Global prescription pharmaceuticals market was estimated $ 1,114 billion in 2015
  • The top-10 pharmaceutical companies in this market had share of over 30% in 2015.
  • A comparative analysis of the top-10 organizations was used to develop a ranking for these companies.
  • The ranking model incorporated six criteria for each organization:
    • Revenues
    • Contribution of top-3 drug products to the revenues
    • Annual growth
    • Investment in R&D
    • Expenses and income
    • Revenue per employee

 

1. Johnson & Johnson (U.S.)

  • Johnson & Johnson (U.S.) is the top-ranked organization in this list.
  • The company had the highest revenues in 2015.
  • Its pharmaceuticals division contributed to 44.85% of its revenues in 2015.
  • The company had one of the largest R&D budgets in 2015.
  • The contribution of its top-3 drugs to the pharmaceutical revenues (35.84%)
  • Remicade, Stelara, and Zytiga were the top-3 drugs for this company in 2015. The combined revenue of these three products was USD 11,266 million in 2015.

 

2. Hoffmann-La Roche AG (Switzerland)

  • Hoffmann-La Roche AG had revenues of USD 50,111 million in 2015.
  • Its pharmaceuticals segment contributed to 77.54% of its revenue in 2015.
  • The company had the highest R&D expenses in 2015 – USD 9,972 million.
  • Avastin, Herceptin, and Rituxan were the top-3 drugs for Roche in 2015. They contributed to 50.53% of the company’s revenue in 2015. All these three products are related to oncology.

 

3. Pfizer Inc. (U.S.)

  • Pfizer Inc. had revenue of USD 48,851 million in 2015.
  • The companies R&D expenses were USD 7,690 million in 2015.
  • The top-3 drugs products of the company contributed 27.09% to the company’s revenue in 2015.
  • Prevenar – 13 has patent expiry horizon of 2026, would help the company maintain its market position.

 

4. Novartis AG (Switzerland)

  • The total revenue for Novartis AG was USD 49,414 million in 2015.
  • The company’s revenues declined by 5.30% over the previous year.
  • The company invested USD 8,935 million in R&D in 2015.
  • The company’s top-3 drugs in 2015 were Glivec, Gilenya, and Lucentis. The combined sales of these 3 products was USD 9,494 million in 2015.

 

5. Bayer AG (Germany)

  • The only German company in this list.
  • The ratio of the proportion of revenue from its top-3 drugs to total revenue was one of the lowest for Pfizer – 33.72% in 2015.

 

6. Merck & Co., Inc. (U.S.) – [MSD outside USA & Canada]

  • Merck & Co., Inc. had total revenue of USD 39,498 million in 2015.
  • Its pharmaceuticals division contributed to 88.06% of this figure in 2015.
  • Invested USD 6,704 million in R&D in 2015

 

7. GlaxoSmithKline plc (U.K.)

  • GlaxoSmithKline plc is the first U.K-based company in this list.
  • It had total revenues of USD 36,566 million in 2015.
  • Invested USD 5,441 million in R&D in 2015.

 

8. Sanofi (France)

  • Sanofi is the only French company in this list.
  • One of the two companies in this list with positive growth rates in 2015.
  • Revenues grew by 8.99% between 2014 and 2015 to reach USD 34,542 million in 2015.
  • The company invested USD 5,092 million in R&D in 2015.
  • Top-3 products – Lantus, Plavix, and Lovenox – contributed only 29.06% to its revenues in 2015.

 

9. Gilead Sciences, Inc. (U.S.)

  • Gilead Sciences, Inc. had the highest growth rates in 2015.
  • Grew by 31.13% between 2014 and 2015, to reach USD 32,639 million in 2015.
  • Invested USD 3,014 million in R&D in 2015.
  • Top-3 drugs – Harvoni, Sovaldi, and Truvada – contributed 55.48% of its revenues in 2015.

 

10. AstraZeneca plc (U.K.)

  • The revenue for AstraZeneca plc was USD 23,641 million in 2015.
  • Invested USD 5,997 million in R&D in 2015.
  • The R&D investments in relation to its revenue was the highest amongst all companies in this list.
  • Crestor’s and Nexium’s patents expire in 2016
  • Symbicort’s expires in 2017

 

Reference: https://igeahub.com/2016/05/06/top-10-pharmaceutical-companies-2016

Share this article : 

1 responses on "Top 10 Pharmaceutical Companies 2015 - Globally"

  1. J&J on top..
    Novartis looks like sinking compared to giants with dipping revenues. GSK future looks bad.

Leave a Message

Your email address will not be published. Required fields are marked *

FREE PHARMA NEWSLETTER VIA EMAIL

Join fastest growing subscribers who benefit from PharmaCrunch’s coverage on "Pharmaceuticals - Must to Know" updates

Testimonial from Subscribers

Read more

Sushil Kumar

Sales - Institutional (Himalaya)
top
2016 © PharmaCrunch All rights reserved
Skip to toolbar